These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 10713619)

  • 1. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report.
    Gertz MA; Lacy MQ; Dispenzieri A
    Bone Marrow Transplant; 2000 Mar; 25(5):465-70. PubMed ID: 10713619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Autologous stem cell transplantation in the treatment of primary systemic amyloidosis].
    Gil L; Komarnicki M
    Pol Merkur Lekarski; 2009 Sep; 27(159):181-4. PubMed ID: 19827724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis.
    Sack FU; Kristen A; Goldschmidt H; Schnabel PA; Dengler T; Koch A; Karck M
    Eur J Cardiothorac Surg; 2008 Feb; 33(2):257-62. PubMed ID: 18096396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
    Sanchorawala V; Seldin DC
    Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
    Chow LQ; Bahlis N; Russell J; Chaudhry A; Morris D; Brown C; Stewart DA
    Bone Marrow Transplant; 2005 Oct; 36(7):591-6. PubMed ID: 16062177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
    Gertz MA; Lacy MQ; Dispenzieri A; Ansell SM; Elliott MA; Gastineau DA; Inwards DJ; Micallef IN; Porrata LF; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2004 Dec; 34(12):1025-31. PubMed ID: 15516945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL).
    Gertz MA; Lacy MQ; Gastineau DA; Inwards DJ; Chen MG; Tefferi A; Kyle RA; Litzow MR
    Bone Marrow Transplant; 2000 Nov; 26(9):963-9. PubMed ID: 11100275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis.
    Kumar S; Dispenzieri A; Lacy MQ; Litzow MR; Gertz MA
    Bone Marrow Transplant; 2001 Aug; 28(4):381-5. PubMed ID: 11571511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.
    Mollee PN; Wechalekar AD; Pereira DL; Franke N; Reece D; Chen C; Stewart AK
    Bone Marrow Transplant; 2004 Feb; 33(3):271-7. PubMed ID: 14647248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant.
    Saba N; Sutton D; Ross H; Siu S; Crump R; Keating A; Stewart A
    Bone Marrow Transplant; 1999 Oct; 24(8):853-5. PubMed ID: 10516696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal perforation early after peripheral blood stem cell transplantation for AL amyloidosis.
    Schulenburg A; Kalhs P; Oberhuber G; Reiter E; Base W; Greinix HT
    Bone Marrow Transplant; 1998 Aug; 22(3):293-5. PubMed ID: 9720746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.